肿瘤细胞治疗研究
英文原题：New developments in immunotherapy for SCLC.
New developments in immunotherapy for SCLC.
小细胞肺癌（SCLC）是一种侵袭性神经内分泌肿瘤，以初始治疗反应显著而著称，随后迅速复发并对后续治疗线产生耐药。
小细胞肺癌（SCLC）是一种侵袭性神经内分泌肿瘤，特点是治疗初始应答显著，但随后迅速复发，并对后续治疗线次产生耐药。免疫治疗新进展正推动更有效治疗策略的发展，早期临床试验数据也显示出良好前景。SCLC很少存在可操作突变，但受体DLL3在SCLC中广泛表达，使其成为潜在免疫治疗靶点。三种新兴治疗选择包括靶向DLL3的双特异性T细胞衔接器、CAR-T 细胞和抗体药物偶联物。多项双特异性T细胞衔接器II期和III期临床试验显示出希望。此外，首批SCLC人体CAR-T细胞临床试验目前正在开展。
Small cell lung cancer (SCLC) is an aggressive form of neuroendocrine neoplasm known for its striking initial response to treatment, followed by fast relapse and refractoriness in response to additional lines of therapy. New advances in immunotherapy are paving the way for more effective treatment strategies and have promising results with early clinical trial data. While SCLC rarely harbors actionable mutations, the receptor DLL3 is extensively present in SCLC, making it a potential target for immunotherapy. Three emerging therapeutic options include bispecific T cell engagers targeting DLL3, chimeric antigen receptor T cells (CAR-T cells), and antibody-drug conjugates. Several phase II and phase III clinical trials for bispecific T cell engagers show promise. Additionally, the first CAR-T cell trials in humans for SCLC are currently underway.
MEMBER ACCOUNT
登录成功会直接打开下一页。
